A cross sectional study on COVID-19 vaccination during pregnancy and its safety, perinatal and neonatal outcomes in a tertiary care hospital

Authors

  • Anita Sitimani ASSOCIATE PROFESSOR, DEPARTMENT OF OBSTETRICS AND GYNECOLOGY, S.S.INSTITUTE OF MEDICAL SCIENCES AND RC, DANAGERE-577005, KARNATAKA, INDIA. http://orcid.org/0000-0001-6415-9772
  • Achala K. P.
  • Bandamma N. S.

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20223489

Keywords:

COVID-19 Vaccination, Covisheild, Pregnancy

Abstract

Background: Pregnant women are more likely to suffer severe COVID-19 illness, during the second wave of the COVID-19 pandemic in India, there were increased pregnant cases of severe COVID-19. Following first wave due to the wild alpha variant, the vaccine efficacy was questioned during second wave caused by beta and omicron. When compared to receiving only two doses, a third dose (booster dose) that was given at least five months following the second dose significantly decreased the rate of COVID-19 symptoms and severe COVID-19 caused by all variants.

Methods: A prospective hospital based cross-sectional study was undertaken at SSIMS AND RC, Davangere. This study was conducted on pregnant women visiting antenatal clinics and delivering at the department of OBG at S. S. hospital, Davangere.

Results: The data was collected from Feb 2022 to April 2022 at our institute in women undergoing delivery with history of COVID 19 vaccination during pregnancy. A total of 188 cases were studied in the following duration, majority of the women belonged to the age group of 26 to 35 years. 54.8% of the cases were multiparous followed by 45.2% of the cases who were primigravida’s. The mean gestational age during admission and delivery of the patients involved in the study was 37.33 weeks, ranging from as early as 27 weeks of gestation to 40 weeks of gestation. There was no significant correlation between the neonatal and maternal complications seen in the study to the number of doses, gestational age and type of vaccine.

Conclusions: Vaccinating everyone is the most effective method of battling the current COVID-19 outbreak. Despite the lack of sufficient clinical data on long-term side effects, the decline in the number of new cases, critically sick patients, and mortality in many nations suggests that vaccines will put an end to the pandemic.

Author Biography

Anita Sitimani, ASSOCIATE PROFESSOR, DEPARTMENT OF OBSTETRICS AND GYNECOLOGY, S.S.INSTITUTE OF MEDICAL SCIENCES AND RC, DANAGERE-577005, KARNATAKA, INDIA.

DEPARTMENT OF OBG.

References

Magon N, Prasad S, Mahato C, Sharma J. COVID-19 vaccine and pregnancy: A safety weapon against pandemic. Taiwanese J Obstet Gynecol. 2022;61(2): 201-9.

Mahajan N, Pophalkar M, Patil S, Yewale B, Chaaithanya I, Mahale S, et al. Pregnancy outcomes and maternal complications during the second wave of coronavirus disease 2019 (COVID-19) in India. Obstet Amp Gynecol. 2021;138(4):660-2.

Naqvi S, Saleem S, Naqvi F, Billah S, Nielsen E, Fogleman E, et al. Knowledge, attitudes, and practices of pregnant women regarding COVID-19 vaccination in pregnancy in 7 low and middle-income countries: An observational trial from the Global Network for women and children’s health research. BJOG. 2022.

Mohapatra S, Ananda P, Tripathy S. Pharmacological consideration of COVID-19 infection and vaccines in pregnancy. J Chin Med Assoc. 2022;85(5):537-42.

Nunes M, Madhi S. COVID-19 vaccines in pregnancy. Trends Mol Med. 2022;28(8):662-80.

Lipkind H, Vazquez-Benitez G, DeSilva M, Vesco K, Ackerman-Banks C, Zhu J, et al. Receipt of COVID-19 vaccine during pregnancy and preterm or small-for-gestational-age at birth eight integrated health care organizations, United States. MMWR. 2022;71(1):26-30.

Review of latest evidence of rare adverse blood coagulation events with AstraZeneca COVID-19 Vaccine (Vaxzevria and Covishield). Available at: https://www.who.int/news/item/16-04-2021-global-advisory-committee-on-vaccine-safety-(gacvs)-review-of-latest-evidence-of-rare-adverse-blood-coagulation-events-with-astrazeneca-covid-19-vaccine-(vaxzevria-and-covishield). Accessed on 20 March 2022.

COVID-19 vaccines and pregnancy. Available at: https://www.who.int/publications-detail-redirect/ WHO-2019-nCoV-FAQ-Pregnancy-Vaccines-2022. Accessed on 20 March 2022.

COVID-19 vaccination. Available at: from: https://www.mohfw.gov.in/pdf/OperationalGuidanceforCOVID19vaccinationofPregnantWoman.pdf. Accessed on 20 March 2022.

Fell DB, Dhinsa T, Alton GD. Association of COVID-19 vaccination in pregnancy with adverse peripartum outcomes. JAMA. 2022;327(15):1478-87.

Lamptey E. Overcoming barriers to COVID-19 vaccination of pregnant women. Gynecol Obstet Clin Med. 2022;2(1):29-33.

Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, et al. Preliminary findings of mRNA covid-19 vaccine safety in pregnant persons. N Engl J Med. 2021;384(24):2273-82.

Downloads

Published

2022-12-28

Issue

Section

Original Research Articles